Journal
LIFE SCIENCES
Volume 282, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2021.119790
Keywords
Alzheimer; Immunotherapy; Genome; Stem cell; Monoclonal antibody; CRISPR
Ask authors/readers for more resources
Alzheimer's disease is a chronic illness with pathological hallmarks of amyloid plaques and neurofibrillary tangles, genetic predisposition, and current treatments being mainly palliative. New therapeutic approaches like stem cell therapy and gene editing are seen as promising directions for the future.
Alzheimer's disease is a chronic lifestyle ailment whose occurrence has come to light with the increasing life expectancy due to better healthcare. The patient burden for AD is set to double by the year 2060 and advancement in research is of utmost importance to combat this problem. AD is characterized by the pathological hallmarks of amyloid plaques and neurofibrillary tangles. The disease has been implicated to have a genetic predisposition. The current treatment strategies are at best ameliorative in nature and offer no substantive cure. Immunotherapeutic approaches employed have shown few therapeutic benefits but the accelerated approval of aducanumab by the US-FDA shows clinical benefit merit. In addition, newer therapeutic approaches are the need of the hour. This review aims to highlight the pathology of the disease, followed by an insight into newer approaches like stem cell therapy and gene editing, focusing on possible CRISPR mediated targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available